Business Wire

CA-VELODYNE-LIDAR

28.9.2021 12:50:20 CEST | Business Wire | Press release

Share
Velodyne Lidar’s Intelligent Infrastructure Solution Selected for Major Deployment in University of California, Irvine Smart Cities Initiative

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced its Intelligent Infrastructure Solution has been selected by the HORIBA Institute for Mobility and Connectivity2 (HIMaC2 ) in the University of California, Irvine (UCI) Samueli School of Engineering. HIMaC2 plans to equip 25 intersections at UCI and the adjacent City of Irvine with Velodyne’s lidar-based Intelligent Infrastructure Solution as part of a major study on improving traffic and energy efficiency, road safety and air quality.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005328/en/

The Intelligent Infrastructure Solution deployment is supported by a $6 million grant recently awarded to HIMaC2 by the Vehicle Technology Office of the U.S. Department of Energy (DOE). HIMaC2 will create a Public Road Network Platform for the development, evaluation and deployment of emerging and future connected and autonomous vehicle (CAV) technologies. The Intelligent Infrastructure Solution combines Velodyne’s award-winning lidar sensors with powerful AI software to monitor traffic networks and public spaces.

Also included in the project are Bluecity, Argonne National Laboratory (ANL), the UCI Institute of Transportation Studies, Toyota Motor of North America, Pony.ai and Hyundai Mobis. Research shows traffic coordination of intersections and CAVs based on reliable data and analytics can reduce congestion between 20-to-30 percent and emissions between 5-to-15 percent while also improving safety.

“The program looks to advance connected and autonomous transportation and show how they can contribute to smarter, safer infrastructure for our communities,” said UCI Engineering Professor Scott Samuelsen, Principal Investigator in the HIMaC2 program. “By deploying Velodyne’s automated monitoring and control in an intersection network, backbone data can be generated and utilized to demonstrate improved safety, energy efficiency and traffic flow to which cities aspire. With its deployment at 25 intersections, this initiative will be the largest lidar-based traffic monitoring solution in the world.”

HIMaC2 will study how traffic coordination can be improved based on reliable data and analytics generated by the Intelligent Infrastructure Solution. By implementing advanced infrastructure monitoring as a V2X (vehicle to everything) solution, the HIMaC2 program will look to generate critical data needed to improve traffic and crowd flow, path planning, and protect vulnerable road users in all weather and lighting conditions. Distinct advantages of the Intelligent Infrastructure Solution include its ability to leverage as few as one unit per intersection which supports scalability. Additionally, lidar sensors do not identify individuals’ facial characteristics, an important privacy factor for civic applications.

“The HIMaC2 program is tackling one of the most challenging and pervasive infrastructure problems that cities face — how to improve traffic flows and safeguard road users,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Velodyne believes that smart infrastructure integrated with connected and autonomous vehicles have the potential to deliver game-changing improvements in roadway efficiency and safety. We look forward to working with the HIMaC2 team to explore how to create a more sustainable, safer future for our transportation infrastructure.”

Velodyne’s Intelligent Infrastructure Solution

Velodyne’s Intelligent Infrastructure Solution creates a real-time 3D map of roads and intersections, providing precise traffic monitoring and analytics that is not possible with other types of sensors like cameras or radar. It reliably collects data in any lighting or weather condition, supporting year-round operation, while also protecting people's privacy. The solution advances safety through multimodal analytics that detect various road users including vehicles, pedestrians, and cyclists. It can predict, diagnose, and address road safety challenges, helping municipalities and other customers make informed decisions to take corrective action. For more information on the Intelligent Infrastructure Solution, contact Velodyne Sales: 669.275.2526, sales@velodyne.com .

About the HORIBA Institute for Mobility and Connectivity2 (HIMaC2 )

Located at the UCI Samueli School of Engineering “Advanced Power and Energy Program (APEP),” HIMaC2 focuses on the electrochemical powerplants (batteries and fuel cells) powering zero-emission vehicles, the integration of the energy and transportation sectors through electricity and hydrogen under a renewable energy paradigm, and the future of emerging connected and autonomous vehicle. The facilities encompass a Vehicle Evolution Laboratory, a Grid Evolution Laboratory, a Connected and Autonomous Mobility Laboratory, and an Analytic Laboratory.

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .

Forward Looking Statements

This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Link:

ClickThru

Social Media:

https://www.facebook.com/VelodyneLidar/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye